铁死亡在酒精性肝纤维化中的作用机制及其相关治疗策略

位志远; 林锋; 吴涛

doi:10.12449/JCH260525

铁死亡在酒精性肝纤维化中的作用机制及其相关治疗策略

DOI: 10.12449/JCH260525

海南医科大学附属海南医院/海南省人民医院感染科，海口 570311

基金项目:

国家自然科学基金 (82160303);

海南省重点研发项目 (ZDYF2021SHFZ050)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：位志远负责分析资料，查找文献，文章撰写；林锋负责修改文章；吴涛负责文章审阅，经费支持。

详细信息

通信作者:
吴涛， wutao1_ren@163.com （ORCID： 0000-0002-3887-645X）

计量
- 文章访问数: 11
- HTML全文浏览量: 2
- PDF下载量: 3
- 被引次数: 0
出版历程
- 收稿日期: 2026-02-09
- 录用日期: 2026-02-24
- 出版日期: 2026-05-20

Ferroptosis in alcoholic liver fibrosis： Mechanism of action and therapeutic strategies

Department of Infectious Diseases，Hainan Affiliated Hospital of Hainan Medical University/Hainan Provincial People’s Hospital，Haikou 570311，China

Research funding:

National Natural Science Foundation of China (82160303);

Key R&D Project in Hainan Province (ZDYF2021SHFZ050)

More Information

Corresponding author: WU Tao， wutao1_ren@163.com （ORCID： 0000-0002-3887-645X）

摘要

摘要: 酒精性肝纤维化是酒精性肝病进展为肝硬化的关键环节，目前缺乏疗效确切的特异性抗纤维化治疗策略。近年来研究发现，铁死亡（一种铁依赖性脂质过氧化的程序性细胞死亡）在酒精相关肝细胞损伤与纤维化进程中发挥重要作用。乙醇代谢产生的活性氧可损伤肝细胞并削弱其抗氧化防御能力，导致铁稳态失衡及脂质过氧化物蓄积，最终触发铁死亡。肝细胞铁死亡通过放大炎症反应及激活肝星状细胞，促进纤维化进展；而选择性诱导已活化的肝星状细胞发生铁死亡则可减轻纤维化，呈现“双刃剑”效应。现有铁死亡干预措施主要聚焦于抗氧化、降低铁负荷或阻断脂质过氧化放大等，初步显示出一定疗效和潜在临床价值，但仍存在作用单一、细胞选择性不足等局限性。未来有望通过纳米递送等手段，实现多通路协同和细胞特异性干预，进一步提升铁死亡调控策略的抗纤维化疗效。
- 肝疾病，酒精性 /
- 肝纤维化 /
- 铁死亡 /
- 过氧化脂质类
Abstract: Alcoholic liver fibrosis is a critical step in the progression of alcoholic liver disease toward liver cirrhosis， yet there is currently still a lack of effective and specific anti-fibrotic therapeutic strategies. Recent studies have shown that as an iron-dependent， lipid peroxidation-driven form of regulated cell death， ferroptosis plays an important role in alcohol-related hepatocellular injury and fibrogenesis. Reactive oxygen species generated during alcohol metabolism can damage hepatocytes， impair their antioxidant defense ability， and lead to disruption of iron homeostasis and accumulation of lipid peroxides， ultimately triggering ferroptosis. Hepatocyte ferroptosis can promote fibrosis by amplifying inflammatory responses and activating hepatic stellate cells， whereas selective induction of ferroptosis in activated hepatic stellate cells may attenuate fibrosis， highlighting the “double-edged sword” effect of ferroptosis. Current interventions against ferroptosis mainly focus on applying antioxidant approaches， reducing iron burden， or blocking the amplification of lipid peroxidation， which have shown preliminary efficacy and a potential clinical value， but there are still limitations such as single-target actions and insufficient cell selectivity. In the future， nanotechnology-based delivery and other targeting strategies may help to realize multi-pathway coordination and cell-specific modulation， thereby improving the anti-fibrotic efficacy of ferroptosis-oriented therapies.
- Liver Diseases， Alcoholic /
- Hepatic Fibrosis /
- Ferroptosis /
- Lipid Peroxides

HTML全文

注： a，ROS驱动的铁稳态紊乱与游离铁池扩增及肠-肝轴相关调控；b，胱氨酸/谷氨酸逆向转运体-GSH-GPX4轴与脂质过氧化；c，蛋氨酸循环-转硫途径；d，Nrf2信号通路与抗氧化基因调控；e，肝细胞铁死亡介导无菌炎症并促进HSC活化与肝纤维化进展。ALF，酒精性肝纤维化；ROS，活性氧；SIRT1，沉默信息调节因子1；LCN2，脂质运载蛋白2；IRP1，铁调节蛋白1；IRE，铁反应元件；Tf，转铁蛋白；DMT1，二价金属转运体1；Fe²⁺，二价铁离子；Fe³⁺，三价铁离子；NCOA4，核受体共激活因子4；·OH，羟基自由基；NADP⁺，氧化型烟酰胺腺嘌呤二核苷酸磷酸；NADPH，还原型烟酰胺腺嘌呤二核苷酸磷酸；GCS，γ-谷氨酰半胱氨酸合成酶；GSS，谷胱甘肽合成酶；GSR，谷胱甘肽还原酶；GSSG，氧化型谷胱甘肽；GSH，还原型谷胱甘肽；GPX4，谷胱甘肽过氧化物酶4；Se，硒；PL-PUFA，含多不饱和脂肪酸的磷脂；PLOOH，磷脂氢过氧化物；PLOO·，磷脂过氧自由基；Keap1，Kelch样ECH相关蛋白1；Nrf2，核转录因子红系2相关因子2；Bach1，BTB与CNC同源蛋白1；Maf，Maf家族转录因子；ARE，抗氧化反应元件；DAMP，损伤相关分子模式；TLR4，Toll样受体4；NF-κB，核因子κB；P2X7，嘌呤能受体P2X7；NLRP3，核苷酸结合寡聚结构域样受体家族热蛋白结构域相关蛋白3；IL-1β，白细胞介素1β；TNF-α，肿瘤坏死因子α；IL-6，白细胞介素6；TGF-β，转化生长因子β；Smad，母系抗十五表态蛋白同源物；Fenton反应，芬顿反应。

图 1 ALF中铁死亡的分子机制与调控网络

Figure 1. Molecular mechanisms and signaling network of ferroptosis in alcoholic liver fibrosis

下载: 全尺寸图片幻灯片

参考文献(47)

[1]	National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for alcoholic liver disease: A 2018 update[J]. J Clin Hepatol, 2018, 34( 5): 939- 946. DOI: 10.3969/j.issn.1001-5256.2018.05.006. 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 酒精性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34( 5): 939- 946. DOI: 10.3969/j.issn.1001-5256.2018.05.006.
[2]	FENG XF, HUANG NF, WU YQ, et al. Alcoholic liver disease in China: A disease influenced by complex social factors that should not be neglected[J]. J Clin Transl Hepatol, 2024, 12( 7): 677- 684. DOI: 10.14218/JCTH.2024.00034.
[3]	ALI N, FERRAO K, MEHTA KJ. Liver iron loading in alcohol-associated liver disease[J]. Am J Pathol, 2023, 193( 10): 1427- 1439. DOI: 10.1016/j.ajpath.2022.08.010.
[4]	SU LJ, ZHANG JH, GOMEZ H, et al. Reactive oxygen species-induced lipid peroxidation in apoptosis, autophagy, and ferroptosis[J]. Oxid Med Cell Longev, 2019, 2019: 5080843. DOI: 10.1155/2019/5080843.
[5]	GANZ T, NEMETH E. Hepcidin and iron homeostasis[J]. Biochim Biophys Acta BBA Mol Cell Res, 2012, 1823( 9): 1434- 1443. DOI: 10.1016/j.bbamcr.2012.01.014.
[6]	LIM D, KIM KS, JEONG JH, et al. The hepcidin-ferroportin axis controls the iron content of Salmonella-containing vacuoles in macrophages[J]. Nat Commun, 2018, 9( 1): 2091. DOI: 10.1038/s41467-018-04446-8.
[7]	ZHANG WL, ZHONG W, SUN Q, et al. Hepatic overproduction of 13-HODE due to ALOX15 upregulation contributes to alcohol-induced liver injury in mice[J]. Sci Rep, 2017, 7( 1): 8976. DOI: 10.1038/s41598-017-02759-0.
[8]	KAGAN VE, MAO GW, QU F, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis[J]. Nat Chem Biol, 2017, 13( 1): 81- 90. DOI: 10.1038/nchembio.2238.
[9]	HOWARTH DL, VACARU AM, TSEDENSODNOM O, et al. Alcohol disrupts endoplasmic reticulum function and protein secretion in hepatocytes[J]. Alcohol Clin Exp Res, 2012, 36( 1): 14- 23. DOI: 10.1111/j.1530-0277.2011.01602.x.
[10]	LUO J, SONG G, CHEN NN, et al. Ferroptosis contributes to ethanol-induced hepatic cell death via labile iron accumulation and GPx4 inactivation[J]. Cell Death Discov, 2023, 9( 1): 311. DOI: 10.1038/s41420-023-01608-6.
[11]	THOUDAM T, GAO H, JIANG YC, et al. Mitochondrial quality control in alcohol-associated liver disease[J]. Hepatol Commun, 2024, 8( 11): e0534. DOI: 10.1097/HC9.0000000000000534.
[12]	YANG WS, SRIRAMARATNAM R, WELSCH ME, et al. Regulation of ferroptotic cancer cell death by GPX4[J]. Cell, 2014, 156( 1-2): 317- 331. DOI: 10.1016/j.cell.2013.12.010.
[13]	FRIEDMANN ANGELI JP, SCHNEIDER M, PRONETH B, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice[J]. Nat Cell Biol, 2014, 16( 12): 1180- 1191. DOI: 10.1038/ncb3064.
[14]	BRIDGES RJ, NATALE NR, PATEL SA. System xc^－ cystine/glutamate antiporter: An update on molecular pharmacology and roles within the CNS[J]. Br J Pharmacol, 2012, 165( 1): 20- 34. DOI: 10.1111/j.1476-5381.2011.01480.x.
[15]	XIE YC, ZHU S, SONG XX, et al. The tumor suppressor p53 limits ferroptosis by blocking DPP4 activity[J]. Cell Rep, 2017, 20( 7): 1692- 1704. DOI: 10.1016/j.celrep.2017.07.055.
[16]	LIU YQ, GU W. p53 in ferroptosis regulation: The new weapon for the old guardian[J]. Cell Death Differ, 2022, 29( 5): 895- 910. DOI: 10.1038/s41418-022-00943-y.
[17]	ROUAULT TA. Hepatic iron overload in alcoholic liver disease: Why does it occur and what is its role in pathogenesis?[J]. Alcohol, 2003, 30( 2): 103- 106. DOI: 10.1016/s0741-8329(03)00102-2.
[18]	OHTAKE T, SAITO H, HOSOKI Y, et al. Hepcidin is down-regulated in alcohol loading[J]. Alcohol Clin Exp Res, 2007, 31( 1 Suppl): S2- S8. DOI: 10.1111/j.1530-0277.2006.00279.x.
[19]	ZHOU Z, YE TJ, DECARO E, et al. Intestinal SIRT1 deficiency protects mice from ethanol-induced liver injury by mitigating ferroptosis[J]. Am J Pathol, 2020, 190( 1): 82- 92. DOI: 10.1016/j.ajpath.2019.09.012.
[20]	DIXON SJ, LEMBERG KM, LAMPRECHT MR, et al. Ferroptosis: An iron-dependent form of nonapoptotic cell death[J]. Cell, 2012, 149( 5): 1060- 1072. DOI: 10.1016/j.cell.2012.03.042.
[21]	LIU CY, WANG M, YU HM, et al. Ferroptosis is involved in alcohol-induced cell death in vivo and in vitro[J]. Biosci Biotechnol Biochem, 2020, 84( 8): 1621- 1628. DOI: 10.1080/09168451.2020.1763155.
[22]	LU YZ, HU JJ, CHEN L, et al. Ferroptosis as an emerging therapeutic target in liver diseases[J]. Front Pharmacol, 2023, 14: 1196287. DOI: 10.3389/fphar.2023.1196287.
[23]	CONRAD M, PRATT DA. The chemical basis of ferroptosis[J]. Nat Chem Biol, 2019, 15( 12): 1137- 1147. DOI: 10.1038/s41589-019-0408-1.
[24]	YANG WS, STOCKWELL BR. Ferroptosis: Death by lipid peroxidation[J]. Trends Cell Biol, 2016, 26( 3): 165- 176. DOI: 10.1016/j.tcb.2015.10.014.
[25]	WANG BQ, WANG Y, ZHANG J, et al. ROS-induced lipid peroxidation modulates cell death outcome: Mechanisms behind apoptosis, autophagy, and ferroptosis[J]. Arch Toxicol, 2023, 97( 6): 1439- 1451. DOI: 10.1007/s00204-023-03476-6.
[26]	ZHENG XG, JIN XD, YE F, et al. Ferroptosis: A novel regulated cell death participating in cellular stress response, radiotherapy, and immunotherapy[J]. Exp Hematol Oncol, 2023, 12( 1): 65. DOI: 10.1186/s40164-023-00427-w.
[27]	IMAI H, MATSUOKA M, KUMAGAI T, et al. Lipid peroxidation-dependent cell death regulated by GPx4 and ferroptosis[M]// Apoptotic and Non-apoptotic Cell Death. Cham: Springer International Publishing, 2016: 143- 170. DOI: 10.1007/82_2016_508.
[28]	LV YH, WU MY, WANG Z, et al. Ferroptosis: From regulation of lipid peroxidation to the treatment of diseases[J]. Cell Biol Toxicol, 2023, 39( 3): 827- 851. DOI: 10.1007/s10565-022-09778-2.
[29]	LYAMZAEV KG, PANTELEEVA AA, SIMONYAN RA, et al. The critical role of mitochondrial lipid peroxidation in ferroptosis: Insights from recent studies[J]. Biophys Rev, 2023, 15( 5): 875- 885. DOI: 10.1007/s12551-023-01126-w.
[30]	SUN LJ, CAO HF, WANG YZ, et al. Regulating ferroptosis by non-coding RNAs in hepatocellular carcinoma[J]. Biol Direct, 2024, 19( 1): 80. DOI: 10.1186/s13062-024-00530-w.
[31]	GAO H, JIN ZM, BANDYOPADHYAY G, et al. Aberrant iron distribution via hepatocyte-stellate cell axis drives liver lipogenesis and fibrosis[J]. Cell Metab, 2022, 34( 8): 1201- 1213. e 5. DOI: 10.1016/j.cmet.2022.07.006.
[32]	HUANG Q, WANG ZY, AN ZM, et al. Effect of NOD-like receptor family pyrin domain containing 3 knockdown on a mouse model of nonalcoholic steatohepatitis induced by high-fat high-carbohydrate diet[J]. J Clin Hepatol, 2024, 40( 5): 952- 960. DOI: 10.12449/JCH240514. 黄倩, 王卓媛, 安梓铭, 等. NLRP3基因敲减对高脂高糖饮食诱导的非酒精性脂肪性肝炎小鼠模型的影响[J]. 临床肝胆病杂志, 2024, 40( 5): 952- 960. DOI: 10.12449/JCH240514.
[33]	GAO B, BATALLER R. Alcoholic liver disease: Pathogenesis and new therapeutic targets[J]. Gastroenterology, 2011, 141( 5): 1572- 1585. DOI: 10.1053/j.gastro.2011.09.002.
[34]	WANG H, WANG HT, XIU TC, et al. A"cocktail" fluorescent probe for multi-ROS imaging unveils ferroptosis-driven liver fibrosis development[J]. Angew Chem Int Ed, 2025, 64( 35): e202506728. DOI: 10.1002/anie.202506728.
[35]	LAI WJ, WANG B, HUANG RS, et al. Ferroptosis in organ fibrosis: From mechanisms to therapeutic medicines[J]. J Transl Int Med, 2024, 12( 1): 22- 34. DOI: 10.2478/jtim-2023-0137.
[36]	FALLOWFIELD JA, JIMENEZ-RAMOS M, ROBERTSON A. Emerging synthetic drugs for the treatment of liver cirrhosis[J]. Expert Opin Emerg Drugs, 2021, 26( 2): 149- 163. DOI: 10.1080/14728214.2021.1918099.
[37]	ZHOU XX, FU YD, CHEN JM, et al. Progress in clinical and basic research of fuzheng Huayu formula for the treatment of liver fibrosis[J]. J Ethnopharmacol, 2024, 327: 118018. DOI: 10.1016/j.jep.2024.118018.
[38]	LIU YQ, ZHANG C, LI JW, et al. An-Luo-Hua-Xian pill improves the regression of liver fibrosis in chronic hepatitis B patients treated with entecavir[J]. J Clin Transl Hepatol, 2023, 11( 2): 304- 313. DOI: 10.14218/JCTH.2022.00091.
[39]	de ANDRADE KQ, MOURA FA, DOS SANTOS JM, et al. Oxidative stress and inflammation in hepatic diseases: Therapeutic possibilities of N-acetylcysteine[J]. Int J Mol Sci, 2015, 16( 12): 30269- 30308. DOI: 10.3390/ijms161226225.
[40]	ZHOU LF, XIAO M, LI YX, et al. Ursolic acid ameliorates alcoholic liver injury through attenuating oxidative stress-mediated ferroptosis and modulating gut microbiota[J]. J Agric Food Chem, 2024, 72( 38): 21181- 21192. DOI: 10.1021/acs.jafc.4c04762.
[41]	SHI JF, LIU YE, WANG Y, et al. Targeting ferroptosis, a novel programmed cell death, for the potential of alcohol-related liver disease therapy[J]. Front Pharmacol, 2023, 14: 1194343. DOI: 10.3389/fphar.2023.1194343.
[42]	LI X, TAO L, ZHONG MJ, et al. Ferroptosis and liver diseases[J]. J Zhejiang Univ Med Sci, 2024, 53( 6): 747- 755. DOI: 10.3724/zdxbyxb-2024-0566. 李欣, 陶亮, 钟美娟, 等. 铁死亡参与肝疾病研究进展[J]. 浙江大学学报(医学版), 2024, 53( 6): 747- 755. DOI: 10.3724/zdxbyxb-2024-0566.
[43]	ZHOU XY, WANG JC, ZHOU SF. Poria cocos polysaccharides improve alcoholic liver disease by interfering with ferroptosis through NRF2 regulation[J]. Aging, 2024, 16( 7): 6147- 6162. DOI: 10.18632/aging.205693.
[44]	TONG J, LAN XT, ZHANG Z, et al. Ferroptosis inhibitor liproxstatin-1 alleviates metabolic dysfunction-associated fatty liver disease in mice: Potential involvement of PANoptosis[J]. Acta Pharmacol Sin, 2023, 44( 5): 1014- 1028. DOI: 10.1038/s41401-022-01010-5.
[45]	PINYOPORNPANISH K, TANTIWORAWIT A, LEERAPUN A, et al. Secondary iron overload and the liver: A comprehensive review[J]. J Clin Transl Hepatol, 2023, 11( 4): 932- 941. DOI: 10.14218/JCTH.2022.00420.
[46]	LIU MX, CAI YT, WANG RJ, et al. Aggregation-induced emission CN-based nanoparticles to alleviate hypoxic liver fibrosis via triggering HSC ferroptosis and enhancing photodynamic therapy[J]. ACS Appl Mater Interfaces, 2024, 16( 26): 33021- 33037. DOI: 10.1021/acsami.4c04361.
[47]	YU YL, ZHANG SL, XU YF, et al. Oral delivery of ferroptosis inducers for effective treatment of hepatic fibrosis[J]. Nano Res, 2024, 17( 8): 7621- 7630. DOI: 10.1007/s12274-024-6725-z.